A New Multidisciplinary Strategy for Using Novel Tunable Immune Response (TIR) Biomaterial Platform Technology as the New Alternative for Treating Immuno-based Diseases
Volume 1 - Issue 2
CC Chu*
-
Author Information
Open or Close
- Rebecca Q. Morgan ‘60 Endowed Chair Professor, College of Human Ecology, Cornell University Ithaca, USA
*Corresponding author:
CC Chu, Endowed Chair Professor, College of Human Ecology, Cornell University Ithaca, NY, USA
Received: August 15, 2019; Published: August 28, 2019
Full Text
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
Innovation in technology is the key element to modernize medical treatment and will have a significant impact on all phrases of our lives, particularly the healthcare upon aging population. Many diseases have the common root on immunology, particularly inflammation, and the current advanced immunotherapy has all based on the biological approach like cytokines to alter the immune response for achieving better therapeutic outcomes. At here, I would like to propose a new multidisciplinary strategy as a new alternative for treating immuno-based diseases via the use of a novel family of tunable immune response (TIR) biomaterial platform technology.
Opinion|